Nutrastar International Inc. is a nutraceutical company engaged in the production and distribution of Chinese Golden Grass based organic and specialty food products.
Chinese Golden Grass is one of the most highly regarded and sought after nutrients in Chinese Culture. Nutrastar is the worlds largest producer.
-Operations are based in Harbin, the capital of Heilongjiang Province and the 10th largest city in China (population 10 million)
-302 employees-with 21 in R&D and 132 in sales and marketing
-Distribution network covers more than 10 provinces in China
This document discusses the merger between Ranbaxy and Daiichi Sankyo. It provides background on both companies and details of the merger deal. Daiichi Sankyo acquired a 63.92% stake in Ranbaxy for $4.98 billion, valuing Ranbaxy at $8.5 billion. The deal gave Daiichi access to Ranbaxy's low-cost manufacturing base and global operations in 56 countries. It provided Ranbaxy benefits like access to new markets, R&D resources, and the Japanese market. A reverse valuation of Ranbaxy found its fair market price to be between INR 467-834 per share.
Cost centers and profit centers affect management decision making in a pharmaceutical company. Cost centers are areas where costs can be tracked, like production or R&D. Profit centers are areas responsible for revenues and expenses. Managers use variance analysis between budgeted and actual costs in responsibility centers to improve efficiency and plan future performance. This allows more focused financial analysis and benchmarking to aid decision making.
A project report on financial analysis of novartis india (1)yashicaj9
The document is a project report on the financial analysis of Novartis India Ltd from 2009-2013. It includes an introduction to the company profile, history, future plans, board of directors, awards and achievements, SWOT analysis, product profile, and research and development. The report will analyze Novartis' annual reports and financial statements from 2011-2012 and 2012-2013 using various financial ratios to evaluate the company's performance and position.
Offers timely update and close follow-up of China’s seed industry dynamics, analyzes market data and finds out factors influencing market development.
It is published monthly by CCM International Limited, which brings you the latest information upon various factors related to China’s seed industry, such as company dynamics, new technology and varieties, market analysis and etc. China’s seed industry has huge market opportunity, high gross profit rate and considerable investment returns. This news helps you find out market potential and opportunities of seed industry.
Shedding Light on Tech Pro Technology (03823.HK)GeoInvesting LLC
• Tech Pro is a company that seems to be suffering from an identity crisis
• We believe the stock price is detached from the reality of our on the ground due diligence and the company’s financials
• Our due diligence raises questions that we believe should be brought to the attention of both the company’s auditor and regulators
• We believe the company will require continued dilutive equity financing to sustain operations
• We are currently short Tech Pro (03823.HK)
One of key strategies I use to find microcap diamonds in the rough is to combine the concepts of Growth + Value. On April 11, 2016, I presented (videos at bottom) at the 2016 Microcap Conference Toronto, where I gave a speech on this very subject. More detail on this presentation can be seen at my blog, http://geoinvesting.com/combining-tenets-growth-value-find-hidden-microcap-opportunities/.
Maj Soueidan Oct 2016 Microcap Conference Philly PresentationGeoInvesting LLC
Inflection points can serve as triggers for you to invest in particular stocks right before the meat of their growth cycles or at a time when they’ve improved their risk profiles for various reasons. I’ve found that the identification of inflection points has helped me pinpoint companies that tend to become acquisition targets. Of over 40 stocks that have been both the focus of our research AND acquired, some of these acquisitions were actually predicted by my team; others were just a byproduct of what happens when good research is rewarded.
Chinese cuisine has a long history dating back 1.7 million years, with new recipes created during each dynasty until peaking in the Qing Dynasty. Chinese food can be divided into eight regional styles including Shandong, Sichuan, Hunan, Guangdong, Fujian, Jiangsu, Zhejiang, and Anhui cuisines, each with distinctive ingredients, flavors, and cooking techniques. Halal Chinese food first appeared over 1,000 years ago and some popular dishes in Pakistan include Szechuan chicken, Chinese fried rice, and egg rolls.
This document discusses the merger between Ranbaxy and Daiichi Sankyo. It provides background on both companies and details of the merger deal. Daiichi Sankyo acquired a 63.92% stake in Ranbaxy for $4.98 billion, valuing Ranbaxy at $8.5 billion. The deal gave Daiichi access to Ranbaxy's low-cost manufacturing base and global operations in 56 countries. It provided Ranbaxy benefits like access to new markets, R&D resources, and the Japanese market. A reverse valuation of Ranbaxy found its fair market price to be between INR 467-834 per share.
Cost centers and profit centers affect management decision making in a pharmaceutical company. Cost centers are areas where costs can be tracked, like production or R&D. Profit centers are areas responsible for revenues and expenses. Managers use variance analysis between budgeted and actual costs in responsibility centers to improve efficiency and plan future performance. This allows more focused financial analysis and benchmarking to aid decision making.
A project report on financial analysis of novartis india (1)yashicaj9
The document is a project report on the financial analysis of Novartis India Ltd from 2009-2013. It includes an introduction to the company profile, history, future plans, board of directors, awards and achievements, SWOT analysis, product profile, and research and development. The report will analyze Novartis' annual reports and financial statements from 2011-2012 and 2012-2013 using various financial ratios to evaluate the company's performance and position.
Offers timely update and close follow-up of China’s seed industry dynamics, analyzes market data and finds out factors influencing market development.
It is published monthly by CCM International Limited, which brings you the latest information upon various factors related to China’s seed industry, such as company dynamics, new technology and varieties, market analysis and etc. China’s seed industry has huge market opportunity, high gross profit rate and considerable investment returns. This news helps you find out market potential and opportunities of seed industry.
Shedding Light on Tech Pro Technology (03823.HK)GeoInvesting LLC
• Tech Pro is a company that seems to be suffering from an identity crisis
• We believe the stock price is detached from the reality of our on the ground due diligence and the company’s financials
• Our due diligence raises questions that we believe should be brought to the attention of both the company’s auditor and regulators
• We believe the company will require continued dilutive equity financing to sustain operations
• We are currently short Tech Pro (03823.HK)
One of key strategies I use to find microcap diamonds in the rough is to combine the concepts of Growth + Value. On April 11, 2016, I presented (videos at bottom) at the 2016 Microcap Conference Toronto, where I gave a speech on this very subject. More detail on this presentation can be seen at my blog, http://geoinvesting.com/combining-tenets-growth-value-find-hidden-microcap-opportunities/.
Maj Soueidan Oct 2016 Microcap Conference Philly PresentationGeoInvesting LLC
Inflection points can serve as triggers for you to invest in particular stocks right before the meat of their growth cycles or at a time when they’ve improved their risk profiles for various reasons. I’ve found that the identification of inflection points has helped me pinpoint companies that tend to become acquisition targets. Of over 40 stocks that have been both the focus of our research AND acquired, some of these acquisitions were actually predicted by my team; others were just a byproduct of what happens when good research is rewarded.
Chinese cuisine has a long history dating back 1.7 million years, with new recipes created during each dynasty until peaking in the Qing Dynasty. Chinese food can be divided into eight regional styles including Shandong, Sichuan, Hunan, Guangdong, Fujian, Jiangsu, Zhejiang, and Anhui cuisines, each with distinctive ingredients, flavors, and cooking techniques. Halal Chinese food first appeared over 1,000 years ago and some popular dishes in Pakistan include Szechuan chicken, Chinese fried rice, and egg rolls.
NBUD - North Bud Farms - Investor Presentation Jan 15th 2019MomentumPR
North Bud Farms Inc. is focused on sustainable, low-cost cannabis production for pharmaceutical development and infused products. It has acquired a late-stage ACMPR applicant with a facility in Quebec. The company is well-positioned for legalization of infused products in 2019. It has an experienced team and plans to use proceeds from a convertible note raise to expand operations and research for consumer products. North Bud aims to be a major low-cost supplier in the growing cannabis market.
NBUD - Northbud Farms Corporate Presentation November 2018MomentumPR
North Bud Farms, through its wholly owned subsidiary GrowPros MMP Inc., which was acquired in February, 2018, is pursuing a licence under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of agricultural land in Low, Que. North Bud Farms will be focused on pharmaceutical- and food-grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October, 2019.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
- Cordlife Group saw its stock price decline after its Chief Executive Officer resigned abruptly in March due to failing to improve earnings and issues with his contract.
- The company appointed a new CEO in July and possesses substantial market share in Asian regions, benefiting from positive market trends like increasing birth rates.
- While Cordlife has high debt levels, it has over 5 times more current assets than current liabilities, and opportunities for significant revenue growth through expanding into developing Asian markets.
The document discusses Mondias Natural Products, a company that specializes in developing and commercializing botanical products for agriculture and healthcare. It highlights several of Mondias' products in development areas like biopesticides and sleeping aids, which target large and growing markets. The summary provides an overview of Mondias' strategy to generate revenue through its Holizen division, pursue partnerships, and expand its product portfolio and sales reach over the next few years.
The document discusses trends in life science investing globally. It notes that while US and European healthcare IPO issuance and market volatility has fluctuated between 2010-2016, overall investment in healthcare IPOs and M&A transactions has generally increased. The document then outlines trends showing increased investment in biotech and life sciences globally, including rising investments in China and more venture capital going to biopharma companies in their Series A rounds. It concludes that given increasing medical spending, longer life expectancies and rapid innovation, it is a good time to start new life sciences businesses.
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
Biocon reported strong financial results for FY13 with 18% revenue growth. Net profit increased 50% due to exceptional items. Key business segments like research services and branded formulations grew over 30%. The company expanded its partnership with Mylan to include development and commercialization of generic insulin analogs. Biocon is progressing several biosimilars programs and expanding globally. It aims to reach $1 billion in sales by 2018 by growing its key business verticals with a focus on emerging markets. The company also reported on its CSR initiatives in healthcare and education in India.
The Indian pharmaceutical market represents one of the most emerging markets worldwide valued at US$8.2 billion. It is expected to be a major global player both domestically and in exports due to its large population, growing economy, and increasing disease burden. The domestic market is projected to grow at a 16% compound annual rate until 2012. Hospitals and institutions contribute 30% of pharmaceutical sales, led by various state health services, insurance programs, and military and corporate hospitals. Institution managers play an important role in developing new business, negotiating with purchase departments, promoting new drugs, and ensuring regulatory compliance for institutional tenders and orders.
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
The pharmaceutical industry is the world's largest industry worth $2.8 trillion globally. The Indian pharmaceutical industry is the third largest by volume and exports 20% of generic drugs worldwide. It has grown significantly over the past two decades and is expected to become the sixth largest pharmaceutical market globally, worth $55 billion by 2020. The industry faces challenges of being highly fragmented, low profit margins due to government price controls, and low research and development investments due to pricing norms. The government is taking initiatives to support the industry through funding and reforms.
Nutrify Today has been working to add value to the responsible nutrition industry to the best of its capacity. In our pursuit of enabling and empowering responsible nutrition businesses; we are happy to bring to you a monthly bulletin on interesting business subjects in responsible nutrition. It will focus on new innovations, new patents, interesting business ideas, and opinions from industry stakeholders globally. We expect this bulletin to be a lead generator, business opportunities generator and potentially triggering of ideas that could lead to great responsible nutrition products. Feel free to contribute, suggest, advise at hello@nutrifytoday.com
EquityNet Research was formed in January 1999 to provide the investing public with professional, independent, objective research on under-followed public companies. This report follows Biostar Pharmaceuticals (OTCBB:BSPM) and was published Feb 17, 2010
NHP - Mondias Investor Presentation - December 2018MomentumPR
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical-based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill's faculty of agricultural and environmental sciences.
This document provides an investor presentation for RedHill Biopharma Ltd. It summarizes the company's drug pipeline including 6 products in various clinical trial phases, with 4 drugs preparing for pivotal phase II/III trials. The company has raised over $12 million and plans to raise approximately $10 million more through an IPO to fund further clinical trials and commercialization efforts. RedHill develops new formulations and uses of existing drugs to treat conditions like Crohn's disease, heart failure, and migraines, pursuing a lower risk business model with significant market potential.
Buy Camlin Fine Sciences for a target of Rs150 - IndiaNivesh IndiaNotes.com
1) Camlin Fine Sciences Ltd is a global manufacturer of food antioxidants and industrial intermediates with customers in America, Europe and Asia. It has several new product launches planned for FY2015 to drive further growth.
2) Camlin recently undertook capacity expansions across most of its product lines including food antioxidants and industrial products like Guaiacol and Tertiary Butyl Catechol to capitalize on growing demand.
3) The company has delivered strong financial growth in recent years and expects to continue its over 25% revenue growth trajectory in FY2015 supported by its capacity expansions and new product lines.
The document provides an executive summary and company goals for Quaker Oats in 2012. The main goals are renewal, growth, and sustainability. Specifically, Quaker Oats aims to improve operations, build its nutrition business, increase availability of healthy snacks, and incorporate more creativity and technology. It also wants to engage consumers through social media, build relationships with other companies, and lead the industry towards more sustainable practices. The summary outlines annual cereal sales trends, Quaker Oats' sales numbers, and a SWOT analysis to help achieve its mission of spreading "Oat Goodness" for another 100 years.
Bio similar- An opportunities or challenge for Indian Company Debashish Kar
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
China Health Labs is a leading provider of total lab solutions and diagnostic equipment and reagents in China. It has four business units focused on rural hospitals, military and emergency services, food safety labs, and large urban hospitals. The company has experienced strong revenue growth in recent years and has a large addressable market supported by Chinese government policies. It has proprietary technology, partnerships with government agencies, and a strategy focused on expanding into new geographic areas and developing new solutions.
This document brings together a set
of latest data points and publicly
available information relevant for
Healthcare Industry. We are very
excited to share this content and
believe that readers will benefit from this periodic publication immensely.
GeoInvesting has a longstanding reputation as short sellers. Our work in exposing more than $10 billion in U.S. listed China based frauds was featured in the recent feature documentary The China Hustle. We also offer portfolio protection for our members, based on the research strategies that have made us extremely well-known for our on the ground due diligence.
There are multiple niches in the microcap space where GeoInvesting’s track record has proven that consistent alpha can be achieved. Each strategy provides favorable percentage returns, but is limited in size. A combination of well-defined strategies can enhance portfolio returns by offering the benefit of diversifying into uncrowded situations with low market correlation without overexposing to a single stock.
We believe the best way for a company of your size to approach a microcap strategy would be to deploy a target capital amount across a few basket portfolios of around 5 stocks each. These baskets can vary by strategy and time horizon. Around these baskets, we can implement one-off ideas as they emerge based on very high probability special situations
More Related Content
Similar to Nutrastar Intl (OTC BB:NUIN) Research Report, June 2010
NBUD - North Bud Farms - Investor Presentation Jan 15th 2019MomentumPR
North Bud Farms Inc. is focused on sustainable, low-cost cannabis production for pharmaceutical development and infused products. It has acquired a late-stage ACMPR applicant with a facility in Quebec. The company is well-positioned for legalization of infused products in 2019. It has an experienced team and plans to use proceeds from a convertible note raise to expand operations and research for consumer products. North Bud aims to be a major low-cost supplier in the growing cannabis market.
NBUD - Northbud Farms Corporate Presentation November 2018MomentumPR
North Bud Farms, through its wholly owned subsidiary GrowPros MMP Inc., which was acquired in February, 2018, is pursuing a licence under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of agricultural land in Low, Que. North Bud Farms will be focused on pharmaceutical- and food-grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October, 2019.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
- Cordlife Group saw its stock price decline after its Chief Executive Officer resigned abruptly in March due to failing to improve earnings and issues with his contract.
- The company appointed a new CEO in July and possesses substantial market share in Asian regions, benefiting from positive market trends like increasing birth rates.
- While Cordlife has high debt levels, it has over 5 times more current assets than current liabilities, and opportunities for significant revenue growth through expanding into developing Asian markets.
The document discusses Mondias Natural Products, a company that specializes in developing and commercializing botanical products for agriculture and healthcare. It highlights several of Mondias' products in development areas like biopesticides and sleeping aids, which target large and growing markets. The summary provides an overview of Mondias' strategy to generate revenue through its Holizen division, pursue partnerships, and expand its product portfolio and sales reach over the next few years.
The document discusses trends in life science investing globally. It notes that while US and European healthcare IPO issuance and market volatility has fluctuated between 2010-2016, overall investment in healthcare IPOs and M&A transactions has generally increased. The document then outlines trends showing increased investment in biotech and life sciences globally, including rising investments in China and more venture capital going to biopharma companies in their Series A rounds. It concludes that given increasing medical spending, longer life expectancies and rapid innovation, it is a good time to start new life sciences businesses.
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
Biocon reported strong financial results for FY13 with 18% revenue growth. Net profit increased 50% due to exceptional items. Key business segments like research services and branded formulations grew over 30%. The company expanded its partnership with Mylan to include development and commercialization of generic insulin analogs. Biocon is progressing several biosimilars programs and expanding globally. It aims to reach $1 billion in sales by 2018 by growing its key business verticals with a focus on emerging markets. The company also reported on its CSR initiatives in healthcare and education in India.
The Indian pharmaceutical market represents one of the most emerging markets worldwide valued at US$8.2 billion. It is expected to be a major global player both domestically and in exports due to its large population, growing economy, and increasing disease burden. The domestic market is projected to grow at a 16% compound annual rate until 2012. Hospitals and institutions contribute 30% of pharmaceutical sales, led by various state health services, insurance programs, and military and corporate hospitals. Institution managers play an important role in developing new business, negotiating with purchase departments, promoting new drugs, and ensuring regulatory compliance for institutional tenders and orders.
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
The pharmaceutical industry is the world's largest industry worth $2.8 trillion globally. The Indian pharmaceutical industry is the third largest by volume and exports 20% of generic drugs worldwide. It has grown significantly over the past two decades and is expected to become the sixth largest pharmaceutical market globally, worth $55 billion by 2020. The industry faces challenges of being highly fragmented, low profit margins due to government price controls, and low research and development investments due to pricing norms. The government is taking initiatives to support the industry through funding and reforms.
Nutrify Today has been working to add value to the responsible nutrition industry to the best of its capacity. In our pursuit of enabling and empowering responsible nutrition businesses; we are happy to bring to you a monthly bulletin on interesting business subjects in responsible nutrition. It will focus on new innovations, new patents, interesting business ideas, and opinions from industry stakeholders globally. We expect this bulletin to be a lead generator, business opportunities generator and potentially triggering of ideas that could lead to great responsible nutrition products. Feel free to contribute, suggest, advise at hello@nutrifytoday.com
EquityNet Research was formed in January 1999 to provide the investing public with professional, independent, objective research on under-followed public companies. This report follows Biostar Pharmaceuticals (OTCBB:BSPM) and was published Feb 17, 2010
NHP - Mondias Investor Presentation - December 2018MomentumPR
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical-based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill's faculty of agricultural and environmental sciences.
This document provides an investor presentation for RedHill Biopharma Ltd. It summarizes the company's drug pipeline including 6 products in various clinical trial phases, with 4 drugs preparing for pivotal phase II/III trials. The company has raised over $12 million and plans to raise approximately $10 million more through an IPO to fund further clinical trials and commercialization efforts. RedHill develops new formulations and uses of existing drugs to treat conditions like Crohn's disease, heart failure, and migraines, pursuing a lower risk business model with significant market potential.
Buy Camlin Fine Sciences for a target of Rs150 - IndiaNivesh IndiaNotes.com
1) Camlin Fine Sciences Ltd is a global manufacturer of food antioxidants and industrial intermediates with customers in America, Europe and Asia. It has several new product launches planned for FY2015 to drive further growth.
2) Camlin recently undertook capacity expansions across most of its product lines including food antioxidants and industrial products like Guaiacol and Tertiary Butyl Catechol to capitalize on growing demand.
3) The company has delivered strong financial growth in recent years and expects to continue its over 25% revenue growth trajectory in FY2015 supported by its capacity expansions and new product lines.
The document provides an executive summary and company goals for Quaker Oats in 2012. The main goals are renewal, growth, and sustainability. Specifically, Quaker Oats aims to improve operations, build its nutrition business, increase availability of healthy snacks, and incorporate more creativity and technology. It also wants to engage consumers through social media, build relationships with other companies, and lead the industry towards more sustainable practices. The summary outlines annual cereal sales trends, Quaker Oats' sales numbers, and a SWOT analysis to help achieve its mission of spreading "Oat Goodness" for another 100 years.
Bio similar- An opportunities or challenge for Indian Company Debashish Kar
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
China Health Labs is a leading provider of total lab solutions and diagnostic equipment and reagents in China. It has four business units focused on rural hospitals, military and emergency services, food safety labs, and large urban hospitals. The company has experienced strong revenue growth in recent years and has a large addressable market supported by Chinese government policies. It has proprietary technology, partnerships with government agencies, and a strategy focused on expanding into new geographic areas and developing new solutions.
This document brings together a set
of latest data points and publicly
available information relevant for
Healthcare Industry. We are very
excited to share this content and
believe that readers will benefit from this periodic publication immensely.
Similar to Nutrastar Intl (OTC BB:NUIN) Research Report, June 2010 (20)
GeoInvesting has a longstanding reputation as short sellers. Our work in exposing more than $10 billion in U.S. listed China based frauds was featured in the recent feature documentary The China Hustle. We also offer portfolio protection for our members, based on the research strategies that have made us extremely well-known for our on the ground due diligence.
There are multiple niches in the microcap space where GeoInvesting’s track record has proven that consistent alpha can be achieved. Each strategy provides favorable percentage returns, but is limited in size. A combination of well-defined strategies can enhance portfolio returns by offering the benefit of diversifying into uncrowded situations with low market correlation without overexposing to a single stock.
We believe the best way for a company of your size to approach a microcap strategy would be to deploy a target capital amount across a few basket portfolios of around 5 stocks each. These baskets can vary by strategy and time horizon. Around these baskets, we can implement one-off ideas as they emerge based on very high probability special situations
The document summarizes the investment strategies and approach of Geoinvesting.com, which focuses on identifying undervalued microcap stocks. Some of their main strategies include buying stocks that are underreacting to good news ("Buy on Pullback"), targeting companies that may be acquisition candidates, and investing in turnaround situations. They provide several case studies of past investments that achieved significant returns, such as NV5 Global, GTT Communications, Zynex, and Vocus, to illustrate how they successfully implemented these strategies.
Dr. Andrew W. Lo - Adaptive Markets: Financial Evolution and the Speed of Tho...GeoInvesting LLC
This document summarizes Andrew Lo's presentation on adaptive markets. Lo discusses how the traditional view of efficient markets based on rational investor behavior is incomplete. He argues markets are adaptive, influenced by human psychology and constantly changing environments. Lo presents his adaptive markets hypothesis, drawing on evolutionary biology and noting markets evolve as individuals compete and learn. This new view has implications for investing, regulation, and developing more sophisticated indexes that account for individual investor needs and behaviors.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Pioneer Power Solutions (PPSI) May 2017 Investor PresentationGeoInvesting LLC
Pioneer Power Solutions, Inc. (PPSI) manufactures, sells and services a broad range of electrical transmission, distribution and on-site power generation equipment in the field of utility, industrial, commercial original equipment manufacturer, and in critical power markets.
This presentation covers:
Transmission and Distribution Solutions - Equipment that distributes, controls, conditions and monitors the flow of electrical energy while protecting critical equipment such as transformers, motors, data center equipment and other machinery.
Critical Power Solutions - Onsite power generation systems, control equipment and services that ensure uninterrupted power to operations in times of emergency and in primary power applications, including data centers
Maj Soueidan Oct 2016 Traders For A Cause PresentationGeoInvesting LLC
Maj Soueidan is the founder of GeoInvesting.com, which helps everyday investors find underfollowed micro-cap stock ideas through information arbitrage. GeoInvesting educates investors, saves them time performing research, and aims to provide institutional-quality ideas. Maj takes advantage of readily available information not found by others to identify inflection points in stocks before they are processed by the broader market. While some of Maj's past ideas have increased over 1,000%, others that were once multi-baggers are now down substantially. GeoInvesting presents elevator pitches on ideas, issues daily reports, and keeps members alerted through social media.
President and Co-Founder of GeoInvesting presented at the 2016 Microcap Conference in Toronto, focusing on stock trading and investing strategies revolving around using a combination of growth and value when selecting investments.
microcapconf.com/conferences/toronto-2016/
April 11, 2016 - Heng Ren White Paper on Chinese BuyoutsGeoInvesting LLC
- 38 Chinese companies have announced management buyouts of US shareholders since 2015, offering below-average premiums. On average, premiums were less than three-quarters of the US average.
- These companies significantly increased their cash holdings after listing in the US, from an average of $46M pre-IPO to $280M at the time of buyout announcements. However, they are squeezing out US investors at prices below fair value and sometimes even below the IPO price.
- After buying out US shareholders, some companies have offered shares in China at much higher values, indicating the buyout offers to US investors were too low and unfairly enriched company management. Regulators need to close loopholes to
Moseda Technologies Company Presentation, November 2015GeoInvesting LLC
Moseda Technologies Inc. primarily engages in the development and operation of mobile device management software systems that allow the management to tracking of assets using mobile devices. It develops SmartCare, a mobile health solution for accessing, tracking, and managing patient health records securely from the Web, smartphone, or tablet; for automatic vital tracking; and for healthcare providers to manage staff and tasks. The company also provides SmartCare@Home, a telemedicine solution that utilizes the mobile, wearables, and SaaS technology to allow for remote patient monitoring. In addition, it offers SmartFleet, a fleet and asset tracking software for businesses that operate mobile and vehicle fleets. The company is headquartered in Vancouver, Canada.
Moseda Technologies Inc. primarily engages in the development and operation of mobile device management software systems that allow the management to tracking of assets using mobile devices. It develops SmartCare, a mobile health solution for accessing, tracking, and managing patient health records securely from the Web, smartphone, or tablet; for automatic vital tracking; and for healthcare providers to manage staff and tasks. The company also provides SmartCare@Home, a telemedicine solution that utilizes the mobile, wearables, and SaaS technology to allow for remote patient monitoring. In addition, it offers SmartFleet, a fleet and asset tracking software for businesses that operate mobile and vehicle fleets. The company is headquartered in Vancouver, Canada.
This CEO will present Phase 2 clinical trial results on November 7th that could revolutionize Alzheimer's treatment. If the results continue the promising early Phase 2A results of 83% of patients benefiting and a 4x improvement in memory over current drugs, the small company's stock could experience unprecedented gains as high as 2,150% as it moves towards Phase 3 trials. The discovery of an effective treatment for Alzheimer's, which currently has no cure, could be worth $67 billion annually and save the US healthcare system from being overwhelmed by rising Alzheimer's costs in the coming decades.
The document summarizes several stock picks and trades made by GeoInvesting between February and April 2015:
- They traded in and out of AMCN based on news and an investment valuing the stock at $8.
- They added to their position in ESCC at $0.40 in March 2015 based on an imminent liability resolution announced in April, causing the stock to rise 100%.
- In April they stated ORBK's muted reaction to strong earnings was a buying opportunity but visibility may only extend a few quarters.
- Several other trades and recommendations over this period included TOUR, HOFT, GBSN, NNBR, NVEE, ISDR, MNTX, BIOQ, LAS
L & L Energy's (LLEN) Dickson Lee Sentencing Memorandum - 2015GeoInvesting LLC
This document is a government sentencing memo recommending a 60 month prison sentence for Dickson Lee, the founder and CEO of coal company L&L Energy. It summarizes that Lee pled guilty to securities fraud for fabricating the existence of a CFO and lying on SEC filings to fraudulently obtain a NASDAQ listing, which boosted the company's stock price. It also claims that later, with the company desperate for cash, Lee secretly issued and dumped over 500,000 shares on the market without disclosure. The memo argues the fraud was severe and undermined market integrity, and that the sentencing guidelines fail to capture the full severity of Lee's actions.
Vocus cloud marketing software analyst day presentation june 6 2012GeoInvesting LLC
- Vocus provides cloud marketing software to help businesses attract, engage and retain customers.
- Digital marketing represents a significant opportunity, with the market expected to grow to $77 billion by 2016.
- Vocus' software suite addresses key functions of modern digital marketing like social, search, email and publicity.
- The company has a scalable and profitable business model focused on the SMB market of $3,000-30,000 customers.
We have reason to believe that the SEC already has Qihoo on its radar. Given the information presented in this report, along with other issues that we have omitted, we believe that Qihoo will be delisted from the NYSE and management charged with securities fraud.
Equity Insights - Sionex (SINX) Research Report May 2012GeoInvesting LLC
Sionix designs, develops, markets, and sells water management and treatment
solutions intended for use in the oil and gas, agriculture, disaster relief, and
municipal (both potable and wastewater) markets. The Company’s Mobile
Water Treatment System (“MWTS”) is configured dependent upon customer
requirements and integrates components and technologies based on those
requirements. Within these systems, the company utilizes a Dissolved Air
Floatation (“DAF”) system with patented technology that management
estimates removes more than 99.95 percent of the organic, and most
inorganic, particles in water. This includes the removal of hydrocarbons,
insoluble metals, infectious bacteria, algae, and color. Historically, DAF systems
similar to the DAF used in Sionix MWTS created bubbles that were 50 microns
or greater, which were unable to remove all contaminants due to their size.
The Sionix technology utilizes and refines DAF technology to provide a pretreatment
process using ambient oxygen and minimal chemical flocculent
aids that can be more efficient and cost-effective. The company’s patented
technology makes micro-bubbles that allow a much greater percentage of
contaminants to be captured, floated to the surface, and skimmed off with
minimal use of chemicals. The Company’s MWTS is mobile and modular such
that it can be transported easily to address a wide range of water treatment
markets and can meet customers’ needs for new systems or to replace or
integrate with existing filtration technologies. Sionix was initially incorporated
in Utah in 1996 and reincorporated in Nevada in 2003. The company’s website
is www.sionix.com.
The document is a presentation from Neenah Paper, Inc. given at an investor conference in February 2012. It provides an overview of Neenah Paper, including:
1) Neenah Paper leads in performance-based technical products and high-end printing papers. It has two business segments: Technical Products and Fine Paper.
2) The company has successfully transformed its business mix and financial performance through strategic acquisitions and focus on specialty markets.
3) Neenah Paper has continued strong financial momentum, with top and bottom line growth, improving margins, and increasing return on capital. A recent acquisition is expected to further drive growth and value creation.
Conclusive Proof that L&L International (LLEN) Does Not Own the Ping Yi MineGeoInvesting LLC
In a red flag alert issued to our premium members Friday, January 13th, 2012, we presented a Chinese SAIC filing and multiple website links showing that the Ping Yi Mine that allegedly represents 37% of LLEN’s production capacity is owned not by LLEN, but by an investment group of four Chinese nationals led by Mr. Hu Shiwei, and that this group is currently offering the mine for sale in China.
Cleantech Innovations (CTEK) files Injunctive Relief Against NASDAQGeoInvesting LLC
Having exhausted all available administrative remedies, CleanTech seeks a temporary
stay, preliminary injunction, and permanent injunction preventing NASDAQ from delisting it from the NASDAQ Stock Exchange, pending CleanTech's appeal of NASDAQ's final delisting
decision to the Securities Exchange Commission ("SEC").
OJP data from firms like Vicinity Jobs have emerged as a complement to traditional sources of labour demand data, such as the Job Vacancy and Wages Survey (JVWS). Ibrahim Abuallail, PhD Candidate, University of Ottawa, presented research relating to bias in OJPs and a proposed approach to effectively adjust OJP data to complement existing official data (such as from the JVWS) and improve the measurement of labour demand.
Independent Study - College of Wooster Research (2023-2024) FDI, Culture, Glo...AntoniaOwensDetwiler
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
Vicinity Jobs’ data includes more than three million 2023 OJPs and thousands of skills. Most skills appear in less than 0.02% of job postings, so most postings rely on a small subset of commonly used terms, like teamwork.
Laura Adkins-Hackett, Economist, LMIC, and Sukriti Trehan, Data Scientist, LMIC, presented their research exploring trends in the skills listed in OJPs to develop a deeper understanding of in-demand skills. This research project uses pointwise mutual information and other methods to extract more information about common skills from the relationships between skills, occupations and regions.
How Does CRISIL Evaluate Lenders in India for Credit RatingsShaheen Kumar
CRISIL evaluates lenders in India by analyzing financial performance, loan portfolio quality, risk management practices, capital adequacy, market position, and adherence to regulatory requirements. This comprehensive assessment ensures a thorough evaluation of creditworthiness and financial strength. Each criterion is meticulously examined to provide credible and reliable ratings.
Seminar: Gender Board Diversity through Ownership NetworksGRAPE
Seminar on gender diversity spillovers through ownership networks at FAME|GRAPE. Presenting novel research. Studies in economics and management using econometrics methods.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
1. Elemental Economics - Introduction to mining.pdfNeal Brewster
After this first you should: Understand the nature of mining; have an awareness of the industry’s boundaries, corporate structure and size; appreciation the complex motivations and objectives of the industries’ various participants; know how mineral reserves are defined and estimated, and how they evolve over time.
Abhay Bhutada, the Managing Director of Poonawalla Fincorp Limited, is an accomplished leader with over 15 years of experience in commercial and retail lending. A Qualified Chartered Accountant, he has been pivotal in leveraging technology to enhance financial services. Starting his career at Bank of India, he later founded TAB Capital Limited and co-founded Poonawalla Finance Private Limited, emphasizing digital lending. Under his leadership, Poonawalla Fincorp achieved a 'AAA' credit rating, integrating acquisitions and emphasizing corporate governance. Actively involved in industry forums and CSR initiatives, Abhay has been recognized with awards like "Young Entrepreneur of India 2017" and "40 under 40 Most Influential Leader for 2020-21." Personally, he values mindfulness, enjoys gardening, yoga, and sees every day as an opportunity for growth and improvement.
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
Eco-Innovations and Firm Heterogeneity.Evidence from Italian Family and Nonf...
Nutrastar Intl (OTC BB:NUIN) Research Report, June 2010
1. Research Report for Nutrastar
International Inc. (NUIN)
by China Growth Partners Inc.
June 15, 2010
1
2. Safe Harbor Statement
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
Any statements set forth herein that are not historical facts are forward-looking statements
that involve risks and uncertainties that could cause actual results to differ materially from
those in the forward-looking statements.
Potential risks and uncertainties include, but are not limited to, such factors as
unanticipated changes in product demand, interruptions in the supply, downturns in the
Chinese economy, changes in applicable laws and/or regulations, and other information
detailed from time to time in the Company's filings and future filings with the United States
Securities and Exchange Commission. Accordingly, although the Company believes that the
expectations reflected in such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct.
2
3. Disclaimer & Disclosure
China Growth Partners Inc. is not an investment advisor and this material is not a solicitation
or recommendation to buy, sell, or hold securities. All statements and opinions contained in
this presentation are the sole opinion of the authors and are subject to change without
notice. We are not liable for any investment decisions made based on this presentation.
All statements and opinions contained in this presentation are based on public information
and information from resources that we believe to be correct. We disclaim any and all
liability as to the completeness or accuracy of the information and for any omissions of
material facts not made known to us. Investing in equities involves risk and you can lose
some or all of your investment. This investment may not be suitable for all investors.
Investors should consider their specific investment goals, objectives and risk tolerance before
investing. Consult an investment advisor or financial planner prior to making any investment
decision.
China Growth Partners Inc. has been hired by American Capital Ventures who has been
engaged for investor relations by Nutrastar International. China Growth Partners Inc. has
received $20,000 USD in compensation for this presentation. As per our preferred business
model, China Growth Partners Inc. is investing 50% ($10,000 USD) of our fee in shares of
NUIN.OB in the open market and will hold those shares for a minimum of 12 months from
the date of this presentation. After such time, China Growth Partners Inc. may retain or sell
its shares at its sole discretion. American Capital Ventures has hired China Growth Partners
Inc. to provide opinions for other issuers. 3
4. Contents
• Company Overview
• Key Investment Points
• About Chinese Golden Grass / Company Products
• Global Market for Chinese Golden Grass
• Barriers to Entry by Competitors
• Patented Processes
• Products
• Sales and Distribution
• Margins
• Revenue Breakdown
• Growth Trends
• Balance Sheet
• 2010 Outlook
• New Product Launches
• Distribution Expansion
• Management
• Summary and 12 Month Price Target
• Contacts
4
5. Overview
Nutrastar International Inc. is a nutraceutical company engaged in the production and
distribution of Chinese Golden Grass based organic and specialty food products.
Chinese Golden Grass is one of the most highly regarded and sought after nutrients in
Chinese Culture. Nutrastar is the worlds largest producer.
Operations are based in Harbin, the capital of Heilongjiang Province and the 10th largest city
in China (population 10 million)
302 employees- with 21 in R&D and 132 in sales and marketing
Distribution network covers more than 10 provinces in China
Ticker: NUIN Market Cap: $45.8M USD Legal: Pillsbury Winthrop
Fiscal Year End: Dec. 31st 2009 Revenue: $15.3M USD Shaw Pittman LLP
Recent Price: $3.15 (on 6/10/2010) 2009 Net Income $7.7M USD New York, NY
52 Week Range: $1.01-$5.00 2009 EPS: .58 Auditor: AGCA, Inc.
Shares Outstanding: 14,312,731 Trailing PE: 5.3 Arcadia, CA
Cash Flow From Operations: $9.3M USD
5
6. Overview
Corporate Structure
Nutrastar International Inc.
(Nevada)
100%
New Zealand WAYNE’S New Resources
Development Co., Ltd. (BVI)
100%
Heilongjiang Shuaiyi New Energy
Development Co., Ltd. (PRC)
100% 100%
Harbin Shuaiyi Green &
Daqing Shuaiyi Biotech
Specialty Food Trading
Co., Ltd. (PRC)
LLC (PRC)
6
7. Key Investment Points
Investment Highlights
• Leadership Position
– Worlds largest Golden Grass planting base
– 19% market share in China for Golden Grass products
– Annual production capacity of 55 tons & expanding to 65 by end of 2010
• Global demand estimated to be 5x greater than China’s total production capacity
• High barriers to entry (patented biotechnology used in cultivation process, with additional patents
pending)
• Extremely high margins (70.2% for2009, increasing to 77.9% in the first quarter of 2010 )
• 66% management ownership
• Strong Research and Development program in cooperation with the China Institute of Science
• Expansion of sales and distribution network currently underway
• Strong balance sheet with $23.3M USD cash
• Steady cash flow from operations ($9.3M USD in 2009)
• Very low Accounts Receivable balance/many customers pay cash upfront
• 2010 “make good” net income $9M USD
• 2011 “make good” net income $11M USD
7
8. Chinese Golden Grass
Chinese Golden Grass, (Cordyceps Militaris), is a species
of parasitic fungus that is typically found in the north-
eastern mountains of China. It is a precious ingredient in
TCM (Traditional Chinese Medicine) as it is widely believed
to offer high medical and health benefits by nourishing
the yin, boosting the yang, and improving lung and kidney
function. Both Eastern and Western research has shown
that Cordyceps Militaris may boost the immune system
and can be used as a supplement for the treatment of Chinese Golden Grass
hypertension, in the treatment of certain cancerous Cordyceps Militaris
tumors, and has been used in treating arteriosclerosis and
gastrointestinal disorders.
In addition to TCM compounds, Chinese Golden Grass is used in organic and specialty foods,
beverages, and other products in China.
An October 2009 research report by the Freedonia Group states that demand for
nutraceutical ingredients worldwide is projected to advance 6.2 percent annually to $21.8
billion USD in 2013. Moreover, the report emphasizes that China and India will emerge as
the most rapidly expanding nutraceutical ingredient markets as strong economic growth
allows them to upgrade and diversify food, beverage and drug production capabilities. 8
9. Global Market
Wild Cordyceps Militaris (Chinese Golden Grass) can cost as much as
$10,000 USD per kilogram according to Georges M. Halpern’s Healing
Mushrooms. Due to a large and growing demand for Chinese Golden
Grass, wild strains have been severely depleted and harvesting is no
longer permitted without government approval.
Global Markets for Chinese Golden Grass are mainly in the United States,
Canada, Japan, Korea, Hong Kong and Southeast Asia. The European and
Australian markets are also emerging.
According to Market Survey of Cordyceps Militaris 2008, published by The
China Market Monitoring Center, the current international market demand
for Cordyceps Militaris is about 1,000 tons a year while Chinese domestic
market demand is about 500 tons/year with an annual growth rate of over
13%. With about 50 Cordyceps Militaris manufacturers in China having an
aggregate production capacity of only 250 tons/year, demand is running 2X
greater than supply in China.
As a result of this tremendous demand , management has reiterated their
confidence to China Growth Partners in meeting the $9M USD and $11M
USD in net income targets for 2010 and 2011 respectively. 9
10. Barriers to Entry
Nutrastar is the market leader in China with a 19% market share, and operates the world’s
largest single source for cultivated Cordyceps Militaris according to the company’s filings.
Multiple Barriers for Competitive Entrants:
Extremely sensitive growing conditions- very difficult to grow in a man-made
environment
Nutrastar developed the patented technology to commercially grow and produce
Cordyceps Militaris
Existing competitors are small-sized local producers with much lower production capacity
and less advanced growing and production technology
As a result of the difficulty in cultivating Chinese Golden Grass, the extreme rarity of wild
strains with government regulations against harvesting them, and Nutrastar’s market leading
position with patents and patents pending in it’s cultivation, barriers to entry for new
competitors are strong and margins should remain high*.
*Gross margins averaged 70.2% for 2009 and increased to 77.9% in Q1 of 2010 10
11. Patented Cultivation
Nutrastar’s highly successful cultivation process is patent-protected.
1 2 3
Major Ingredient: Minor ingredient: Wild strains:
Mainly wheat, rice, etc. Culture fluid formulation Artificially selecting wild strains
Shaking table: Special steamer: 5
4 Culture fluid formulation and wild strains Plant strains into the culture medium after high
placed into the shaking table & propagated temperature sterilizing.
Inoculation: Spawn running: 7
6 Propagated strains are placed into the Propagated strains require spawn running with
culture medium. and without light. After about 30 to 35 days, the
myceliums are mature.
9
Cultivation: Harvest:
8 Period of growth in the presence of light at After growing about 30 days, it's harvested.
a certain temperature and humidity.
11
10 Drying: Packing:
The harvested fresh Golden Grass is dried Dried grass is packaged in small packages and
sold over the market counter. Other dried grass
is packaged in large packages and sold to
pharmaceuticals companies as raw materials. 11
12. Products
1) Chinese Golden Grass: Cultivate, process, market and distribute to:
Raw Material: Pharmaceutical companies
Retail stores: drug stores, supermarkets, and franchise stores
2) Organic and Specialty Food (wholesale distribution):
Sales agent or distributor for third-party producers.
Largest wholesale distributor of organic and specialty
food in Heilongjiang Province (population 37 million)
3) Specialty Beverage Products (derived from Chinese Golden Grass):
Commercial launch slated for first half of 2010
(See New Product Launches slide for more information on what could
be a blockbuster product launch for Nutrastar this year)
12
13. Sales & Distribution
Major distributors located in Shangdong, Currently has 115 dedicated sales personnel
Zhejiang, Guangdong, Sichuan, Shang Xi and 9 major distributors covering 10 provinces
province and Beijing, with access points in China delivering:
throughout China.
1) Large-pack products to pharmaceutical
companies
Heilongjiang
2) Small-pack products to drug stores,
supermarkets and franchise stores
Beijing
Major distributors located in Shangdong,
Shandong
Zhejiang, Guangdong, Sichuan, Shang Xi
Jiangsu
province and Beijing, with access points
Shaanxi
Shanghai
throughout China.
Sichuan
Hubei
Chongqing Zhejiang
Hunan Direct sales staff and distributors participate in
Fujian
large trade shows and offer seminars and
Guangdon
g lectures to local communities
13
14. Extremely High Margins
90% Gross Margins
78%
80% 70%
70% 62% 65%
60%
50% 44%
40%
30%
20%
10%
0%
2006 2007 2008 2009 Q1 2010
China Growth Partners expects margins to remain high as launch of Specialty Beverage
Products and other higher margin small-pack products are distributed to drug stores,
supermarkets, and franchise stores.
14
Past performance does not necessarily predict future results.
15. Revenue Breakdown
2009 Revenue 1st Quarter 2010
Chinese Golden Grass Chinese Golden Grass
Organic & Specialty Foods Organic & Specialty Foods
11%
21%
79% 89%
2009 Golden Grass Sales
Raw Material Retail Stores Management: “We anticipate incremental
revenue and earnings growth of our higher
margin Chinese Golden Grass products .”
29%
71%
15
16. High Growth Trends
Nutrastar experienced impressive growth during the weakest global economy in decades.
Demand for Chinese Golden Grass only increased during this period.
$16.0 Revenue and Net Income in Millions of USD $15.3
$14.0 $13.0
$12.0
$10.0 $9.2
$7.7
$8.0
$5.2 $5.8
$6.0 $4.3
$4.0
$1.7
$2.0
$0.0
2006 2007 2008 * 2009
Revenue (in millions of USD) Net Income (in millions of USD)
*Excludes one-time non-cash merger costs of $2.1 million USD in Fourth Quarter 2008
16
Past performance does not necessarily predict future results.
17. High Growth Trends
Nutrastar International has experienced high growth from 2007-2009. Average period
revenue growth was 30%, average gross profit growth was 38.5%, average net income
growth was 22%, and average growth in income from operations was 31.5%. Net cash
from operating activities has grown by a very impressive 43.5% in the period.
Revenue, Gross Profit, Net Income, Income from Operations, and Net Cash Provided by Operating Activities below all in millions of USD.
2007 2008 Growth 2008 2009 Growth
Revenue $9.2M $13M 41% $12.9M $15.3 18%
Gross Profit $5.7M $8.4M 47% $8.4M $10.8M 28%
Net Income $5.2M $5.8M* 11.5% $5.8M* $7.7M 33%
Income From Operations $5.2M $6.7M 30% $6.7M $8.9M 33%
Net Cash Provided by $4.5M
* Excludes $2.1M in one-time non-cash$6.5M in 2008 related to the merger
$6.5M 44%
charges
$9.3M 43%
Operating Activities
EPS (fully diluted) ----- ----- ----- .49* .58 20%
*Excludes one-time non-cash merger costs of $2.1 million in Fourth Quarter 2008
Projected 2010 Growth:
Q1 2010 Net income was approximately $2.72 M USD, a 25.3% increase over the same
period last year and puts the company well on track to meet their $9M USD in net income
target for 2010. EPS in Q1 was .19/share.
17
Past performance does not necessarily predict future results.
18. Low AR Balance
Most Chinese pharmaceutical and nutraceutical companies have large Accounts Receivable
balances that sometimes carry over quarter to quarter, with long DSO (Days Sales Outstanding)
periods.
Nutrastar has an Accounts Receivable balance that is the lowest China Growth Partners has
seen in China’s nutraceutical sector. For 2009 the company reported $15.3M USD in sales, and
the AR balance on 12/31/2009 was a mere $215,000.
This extremely low AR balance is because many customers pay up front with cash for
Nutrastar’s products. China Growth Partners believes this fact confirms the market’s large
supply-demand imbalance for Nutrastar’s products.
The market supply leadership position (and power) that Nutrastar has can be seen in their
continually low AR balances, the willingness of customers to pay cash in advance for their
products, and gross margins > 70%.
18
19. Strong Balance Sheet
March 31 December 31
Balance sheet very strong with $23.3M cash, total liabilities $10.4M, 2010 2009
current ratio 2.3, $19.6M in retained earnings, and very low AR balance. ( Unaudited ) ( Audited )
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 23,289,425 $ 20,115,677
Accounts receivable, net 367,966 215,486
Inventories 538,700 616,073
Prepayments and other receivables 10,971 251,235
Total current assets 24,207,062 21,198,471
OTHER ASSETS
Intangible assets, net 2,638,241 2,747,402
Property, plant and equipment, net 10,261,227 10,396,507
Total assets $ 37,106,530 $ 34,342,380
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 55,599 $ 863
Other payables and accruals 430,056 453,504
Payable for intangible asset 878,953 878,709
Income tax payable 277,183 319,873
Due to related parties 49,807 49,794
Acquisition payable 8,736,833 8,736,833
Total current liabilities 10,428,431 10,439,576
Total liabilities 10,428,431 10,439,576
Common stock, $0.001 par value, 190,000,000 shares authorized, 14,312,731 and 14,297,731 shares issued and outstanding 14,313 14,298
Additional paid-in capital 4,761,251 4,715,891
Statutory reserves 1,344,401 1,341,687
Retained earnings 19,576,360 16,858,012
Accumulated other comprehensive income 981,774 972,916
Total shareholders' equity 26,678,099 23,902,804
Total liabilities and shareholders' equity $ 37,106,530 $ 34,342,380
19
20. 2010 Outlook
Management has made positive statements for 2010 growth:
“During 2010, Nutrastar plans to further increase total revenue generated through sales of
Chinese Golden Grass, both through increased sales of product processed and packaged
for the consumer marketplace, as well as sales of raw material to the pharmaceutical
industry. The Company expects that further product awareness, widespread availability
and increased health awareness among Chinese consumers will drive consumer adoption
and sales for the Company's Golden Grass.”
and…
“A major initiative of Nutrastar's future growth strategy is the introduction of new, value-
added products targeting multiple downstream markets, including mass consumer,
nutraceutical and pharmaceutical markets. After successfully introducing the small
package consumer cordyceps products, the Company's growth plan during 2010 will
include introducing a new branded specialty beverage product known as "Golden Grass
Energy Drink". Commercialization of Golden Grass Energy Drink is scheduled for the
second quarter of 2010, targeting affluent, professional, athletic and elderly consumers.
In support of its growth strategies, Nutrastar plans to increase annual production capacity
from its current capacity of 55 tons to 65 tons by the end of 2010.”
20
21. New Product Launches
2010 will be an exciting year for Nutrastar International with the launch of their new
Specialty Beverage Product as well as a new Cordycepin Compound.
“Golden Grass Energy Drink”
This specialty beverage targets affluent, professional, athletic and elderly
consumers. Marketable health benefits include enhancing immunity,
reducing fatigue, and increasing circulation.
Golden Grass Energy Drink
Cordycepin Compound
Eastern and Western studies agree that Cordycepin is an agent that has
shown promise in cancer research (specifically in tumor size reduction)
and in boosting the immune system.
Investors may wish to search the Internet for “Antitumor effects of
Cordycepin”, “Cordycepin and Cancer”, and “Cordycepin and Immune
Cordycepin
System” to appreciate the potential of this new compound for Nutrastar.
Chemical Name: 3'-Deoxyadenosine
21
22. New Product Launches
China Growth Partners believes the launch of the “Golden Grass Energy Drink” has the
potential to add substantial revenues and income to the company in 2010-2011.
The target market is more affluent, professional/upwardly mobile consumers and the rapidly-
growing middle class that are turning China into more of a consumer-based economy.
China’s consumer market is on track to become #1 in the world.
Credit Suisse expects China’s share of global consumption to increase from
5.2% at $1.72 trillion USD to 23.1% at $15.94 trillion USD by 2020, overtaking
the US as the largest consumer market in the world. (click to article)
As China’s rural population moves into urbanized areas, “stress and fatigue”
have been reported by 88.9% of respondents in an April 2010 Beijing-based
survey. (click to article)
Nutrastar’s “Golden Grass Energy Drink” will be marketed as a fatigue-
fighter to one of China’s most fastest growing demographics: The
increasingly stressed and fatigued new middle class.
22
23. Distribution Expansion
Currently expanding to a nationwide reach The company’s previous sales depended
for rapid growth in sales. heavily on the sales of large-pack products to
pharmaceutical companies.
To support rapid growth in sales and revenue,
Nutrastar plans to expand their distribution
Heilongjiang
network by selling small-pack, higher margin
products through drug stores, supermarkets
Beijing
and franchise stores.
Shandong
Nutrastar maintains constant communications
Shaanxi
Jiangsu
with distributors to stay informed regarding
Sichuan
Hubei
Shanghai
consumer preferences and market trends in
Chongqing Zhejiang
Hunan order to develop new products, and organize
Fujian
monthly product promotion meetings with
Guangdon
g distributors to increase sales of small package
products.
23
24. Strong Management
Experienced, strong management team.
Management ownership in NUIN is approximately 66%.
Ms. Lianyun Han---Chief Executive Officer, President and Chairperson, with over 10 years
experience in green and organic food business; Shuaiyi Group Founder, Chief Executive
Officer, President and Chairperson; Heilongjiang Daily Reporter, Director, Senior
economist; Harbin University Bachelor Degree.
Ms. Xue Wang---CFO, was a financial executive at Harbin Zhongchang Clean Energy
Development Co., Ltd., a company engaged in the recycling energy business. Ms. Wang
joined our subsidiary Heilongjiang Shuaiyi New Energy Development Co., Ltd. in 2007 as
Financial Manager and became Financial Controller in 2009. She holds a Bachelor's
degree in Accounting from Harbin University of Commerce.
Mr. Lichen Wang,---CTO, Shuaiyi Group Chief Technology Officer, Institute of Edible Fungus of
Three provinces in Northeast China Technician, Deputy Director: Heilongjiang August 1st
Land Reclamation University Bachelor Degree majored in Edible Fungus.
Mr. Hongbing Hua,---CMO, JDB Group Planning General Counsel, instrumental in Wang Lao
Ji Herbal Tea becoming a nationwide beverage brand; Beijing Huiyuan Beverage and
Food Group Co., Ltd. Vice President & Planning Director, instrumental in Huiyuan
becoming the No.1 juice brand in China since 2001.
There is no family relationship between Xue Wang and Lichen Wang.
24
25. Summary & Price Target
China Growth Partners finds Nutrastar International extremely undervalued at the current
trading price and assigns a 12 month price target of $6.30/share based on the following:
Market leader and world’s largest producer of Low AR balance, cash customers, confirms strong
Chinese Golden Grass demand for products
High barriers to entry for potential competition High margin “Golden Grass Energy Drink” launch
imminent
Extremely efficient, patented cultivation process
Management has repeated to us their
Very high margins likely to continue with launch confidence in “Make Good” targets of $9M in net
of higher margin products income for 2010 and $11M in net income for 2011
High management ownership (66%) China Growth Partners expects fully diluted
earnings per share for 2011 to be .61-.65, (at
Strong balance sheet with $23M cash on hand minimum), and assigns a pe multiple of 10 . As a
and consistently cash flow positive result we believe the stock should be trading at
$6.30+ a year from now.
20% capacity expansion by end of 2010
China Growth Partners is investing 50% of our
Expanding sales and distribution network fee in NUIN shares in the open market for a 12
month minimum hold.
25
26. Summary & Price Target
NUIN Closing Price Chart China Growth Partners believes
$6.00
markets are often inefficient and may
$5.00 persistently misprice securities for
$4.00 long periods of time, but that
$3.00 protection against this can be found
$2.00 in growth. As a company grows the
$1.00 value increases, and eventually the
$0.00 market price will increase to reflect
1/20/2010 2/20/2010 3/20/2010 4/20/2010 5/20/2010
that value.
Closing Price
While based on our research and the information in this presentation China Growth Partners believes Nutrastar International’s current share
price to be undervalued and assigns a 12 month share price target of $6.30/share, no assurances can be made that our price target will be
met. Potential risks and uncertainties include, but are not limited to, such factors as unanticipated changes in product demand, interruptions
in the supply, downturns in the Chinese economy, changes in applicable laws and/or regulations, and other information detailed from time to
time in the Company's filings and future filings with the United States Securities and Exchange Commission.
26
27. Contacts
Corporate Address
7/F Jinhua Mansion
41 Hanguang Street
Nangang District, Harbin, 150080
Peoples Republic of China
Phone: (86) 451-82287746
Web site: http://www.syxny.net
Investor Relations
Howard Gostfrand
American Capital Ventures
Phone: (305) 918-7000
Email: info@amcapventures.com
27